Pfizer - Technology Times

After second dose, Pfizer’s efficacy declined from 96% down to 84%

The Pfizer-BioNTech vaccine’s efficacy against SARS-CoV-2 peaked at 96.2% at seven days to two months after the second dose and

Yesterday, brought the good news that Pfizer and its partner BioNTech would start manufacturing its COVID-19 vaccines in Africa, for Africa. By ERIKA

Pfizer and BioNTech said they would seek authorization for a third dose of their Covid-19 vaccine to boost its efficacy

Pfizer is planning to seek U.S. authorization for a third dose of its COVID-19 vaccine, saying Thursday that another shot

Pfizer plans to tap the mRNA technology to make new vaccines for other viruses following the success of its Covid-19